Cargando…

The Amyloid, Tau, and Neurodegeneration (A/T/N) Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up

BACKGROUND: The unbiased amyloid, tau, and neurodegeneration (A/T/N) classification is designed to characterize individuals in the Alzheimer continuum and is currently little explored in clinical cohorts. OBJECTIVE: A retrospective comparison of the A/T/N classification system with the results of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grøntvedt, Gøril Rolfseng, Lauridsen, Camilla, Berge, Guro, White, Linda R., Salvesen, Øyvind, Bråthen, Geir, Sando, Sigrid Botne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242836/ https://www.ncbi.nlm.nih.gov/pubmed/32116257 http://dx.doi.org/10.3233/JAD-191227

Ejemplares similares

Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden
por: Grøntvedt, Gøril Rolfseng, et al.
Publicado: (2022)

Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study
por: Lauridsen, Camilla, et al.
Publicado: (2016)

Cerebrospinal Fluid Aβ43 Is Reduced in Early-Onset Compared to Late-Onset Alzheimer’s Disease, But Has Similar Diagnostic Accuracy to Aβ42
por: Lauridsen, Camilla, et al.
Publicado: (2017)

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease
por: Giannisis, Andreas, et al.
Publicado: (2022)

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study
por: Berge, Guro, et al.
Publicado: (2016)

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
por: Patra, Kalicharan, et al.
Publicado: (2018)

Incidence of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2020)

The Prevalence and Subtypes of Young Onset Dementia in Central Norway: A Population-Based Study
por: Kvello-Alme, Marte, et al.
Publicado: (2019)

Time to Diagnosis in Young Onset Alzheimer’s Disease: A Population-Based Study from Central Norway
por: Kvello-Alme, Marte, et al.
Publicado: (2021)

The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
por: Twohig, Daniel, et al.
Publicado: (2018)

Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer’s Disease
por: Almdahl, Ina S., et al.
Publicado: (2017)

Detecting At-Risk Alzheimer’s Disease Cases
por: Fladby, Tormod, et al.
Publicado: (2017)

β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population
por: Rosenberg, Anna, et al.
Publicado: (2022)

Cohort study of electroencephalography markers of amyloid-tau-neurodegeneration pathology
por: Tanabe, Sean, et al.
Publicado: (2020)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort
por: Berge, Guro, et al.
Publicado: (2014)

Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer’s disease
por: Delmotte, Koen, et al.
Publicado: (2021)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
por: McCollum, Lauren E., et al.
Publicado: (2021)

Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
por: Iaccarino, Leonardo, et al.
Publicado: (2017)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration
por: Gijs, Marlies, et al.
Publicado: (2021)

Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer’s disease: protocol for the ExPlas study
por: Tari, Atefe R, et al.
Publicado: (2022)

Correction: Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K., et al.
Publicado: (2018)

Participation of Amyloid and Tau Protein in Neuronal Death and Neurodegeneration after Brain Ischemia
por: Pluta, Ryszard, et al.
Publicado: (2020)

Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia
por: Vipin, Ashwati, et al.
Publicado: (2022)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders
por: Ma, Ling-Zhi, et al.
Publicado: (2021)

Biomarkers of Inflammation Increase with Tau and Neurodegeneration but not with Amyloid-β in a Heterogenous Clinical Cohort
por: Michopoulou, Sofia, et al.
Publicado: (2022)

The role of tau in neurodegeneration
por: Gendron, Tania F, et al.
Publicado: (2009)

Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus
por: Ali, Tahir, et al.
Publicado: (2015)

The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease
por: Sato, Naoyuki, et al.
Publicado: (2015)

Mild behavioral impairment is associated with β‐amyloid but not tau or neurodegeneration in cognitively intact elderly individuals
por: Lussier, Firoza Z., et al.
Publicado: (2020)

Brain alterations in the early Alzheimer’s continuum with amyloid-β, tau, glial and neurodegeneration CSF markers
por: Salvadó, Gemma, et al.
Publicado: (2022)

Glial activation and inflammation along the Alzheimer’s disease continuum
por: Nordengen, Kaja, et al.
Publicado: (2019)

Tau and DNA Damage in Neurodegeneration
por: Colnaghi, Luca, et al.
Publicado: (2020)

Sleep spindles, tau, and neurodegeneration
por: Neylan, Thomas C, et al.
Publicado: (2022)

Tau as a Biomarker of Neurodegeneration
por: Holper, Sarah, et al.
Publicado: (2022)

Participation of Amyloid and Tau Protein in Post-Ischemic Neurodegeneration of the Hippocampus of a Nature Identical to Alzheimer’s Disease
por: Pluta, Ryszard, et al.
Publicado: (2021)

Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology
por: Hickman, L. Brian, et al.
Publicado: (2023)

The short-term effect of a modified comprehensive geriatric assessment and regularly case conferencing on neuropsychiatric symptoms in nursing homes: a cluster randomized trial
por: Stensvik, Geir-Tore, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_217i87tafoqg8sc5c1tl5ufdjf